Gilbert syndrome

Background

• Gilbert syndrome is the most common inherited disorder of bilirubin metabolism, affecting approximately 5-10% of the general population. It is caused by reduced activity (~30% of normal) of the hepatic enzyme UGT1A1 (uridine diphosphate-glucuronosyltransferase 1A1), resulting in mild, intermittent unconjugated (indirect) hyperbilirubinemia. Gilbert syndrome is entirely benign and does not cause liver disease, hepatic decompensation, or increased mortality.
• The emergency physician's role is to recognize the characteristic pattern (isolated unconjugated hyperbilirubinemia with completely normal liver function), avoid unnecessary workup and hospitalization, provide reassurance, and be aware of drug metabolism implications that may be relevant to ED prescribing.
• Autosomal recessive (most common inheritance pattern); prevalence 3-7% in Caucasians; higher in some African populations
• Male predominance (~3:1 male-to-female ratio)
• Typically recognized in adolescence or early adulthood — often discovered incidentally on routine blood work or during a stressor (illness, fasting)
• UGT1A1 enzyme activity is reduced to approximately 30% of normal
• UGT1A1*28 polymorphism (extra TA repeat in the TATA box promoter region) is the most common genetic variant in Caucasian and African populations; different variants (UGT1A1*6) predominate in Asian populations

Why it matters in the ED

• Gilbert syndrome is extremely common — in a busy ED, multiple patients on any given day may have it
• It is the most frequent cause of isolated unconjugated hyperbilirubinemia encountered by EM physicians
• The primary EM pitfall is ordering unnecessary workup (hepatitis serologies, imaging, hematologic testing, subspecialty referral) for what is a benign condition
• The secondary EM pitfall is attributing jaundice to Gilbert syndrome when a more serious condition is present — Gilbert syndrome is a diagnosis of exclusion and should only be invoked when all other causes of unconjugated hyperbilirubinemia have been reasonably ruled out

Clinical features

Typical presentation

• Patient (often young adult male) presents to the ED for another reason and is found to have mildly elevated total bilirubin on labs, OR presents with mild scleral icterus noticed by themselves or others
• Total bilirubin typically <3 mg/dL (rarely up to 5-6 mg/dL); predominantly unconjugated (indirect)
• All other liver function tests are completely normal: AST, ALT, alkaline phosphatase, GGT, albumin
• No hepatosplenomegaly
• No abdominal pain, pruritus, dark urine, or acholic stools
• No signs of hemolysis (normal reticulocyte count, haptoglobin, LDH, peripheral smear)

Triggers that may precipitate visible jaundice

• Fasting/caloric restriction (the most well-known trigger — bilirubin rises with reduced caloric intake)
• Intercurrent illness (any febrile illness, infection)
• Dehydration
• Physical overexertion
• Menstruation
• Sleep deprivation
• Emotional stress
• Surgery/anesthesia

What Gilbert syndrome does NOT cause

• No liver disease, cirrhosis, or hepatic decompensation — ever
• No abdominal pain (pain attributed to Gilbert syndrome in older literature is no longer considered part of the condition; investigate other causes)
• No fatigue (fatigue and asthenia previously attributed to Gilbert syndrome are no longer considered features; evaluate other etiologies if present)
• No conjugated hyperbilirubinemia — if the direct fraction is elevated, this is NOT Gilbert syndrome

Differential diagnosis

Unconjugated hyperbilirubinemia (the relevant differential)

• Gilbert syndrome (most common; diagnosis of exclusion)
• Hemolytic anemias: hereditary spherocytosis, G6PD deficiency, sickle cell disease, autoimmune hemolytic anemia, TTP/HUS, mechanical hemolysis (prosthetic valve)
• Resorbing hematoma (large bruise, retroperitoneal hemorrhage)
• Ineffective erythropoiesis (megaloblastic anemia, thalassemia)
• Crigler-Najjar syndrome: type 1 (complete UGT1A1 absence; severe neonatal jaundice; bilirubin >20 mg/dL; risk of kernicterus) or type 2 (partial deficiency; bilirubin typically 6-20 mg/dL; responds to phenobarbital)
• Heart failure (impaired hepatic bilirubin uptake from congestion)
• Portosystemic shunts
• Medications: rifampin, probenecid, some HIV antivirals
• Wilson disease (rare; can cause unconjugated hyperbilirubinemia from hemolysis)

Conditions that Gilbert syndrome may coexist with (additive effect)

• G6PD deficiency + Gilbert syndrome: the combination significantly increases risk of severe neonatal hyperbilirubinemia and may cause more pronounced jaundice during hemolytic episodes in adulthood
• Hereditary spherocytosis + Gilbert syndrome: similarly additive
• Gilbert syndrome alone does not cause neonatal kernicterus, but when combined with hemolytic conditions, it can amplify neonatal hyperbilirubinemia to dangerous levels

Evaluation

The ED evaluation should be minimal

• Fractionated bilirubin (total and direct): confirms that hyperbilirubinemia is unconjugated (indirect) — this is the essential first step
• Hepatic panel (AST, ALT, alkaline phosphatase, albumin): must be entirely normal to attribute jaundice to Gilbert syndrome
• CBC with reticulocyte count: to exclude hemolysis (reticulocyte count should be normal in isolated Gilbert syndrome)
• Peripheral blood smear: if hemolysis is suspected (spherocytes, schistocytes, sickle cells)
• Haptoglobin, LDH: to exclude hemolysis (should be normal in Gilbert syndrome)

Criteria that support Gilbert syndrome (diagnosis of exclusion)

• Isolated unconjugated hyperbilirubinemia (total bilirubin typically <3 mg/dL; direct fraction normal)
• All liver enzymes and synthetic function tests normal
• No evidence of hemolysis (normal reticulocyte count, haptoglobin, LDH, smear)
• No evidence of structural liver disease
• History of intermittent mild jaundice, often with identifiable triggers
• Often positive family history (autosomal recessive)

Tests that are NOT needed

• Genetic testing (UGT1A1 genotyping): not required for diagnosis in most cases; considered obsolete as a routine diagnostic tool
• Fasting test: historically used (24-48 hour fast provokes bilirubin rise); no longer recommended as a diagnostic maneuver
• Phenobarbital test: historically used (phenobarbital reduces bilirubin by inducing UGT1A1); obsolete
• Liver biopsy: never indicated
• Hepatobiliary imaging: not needed if liver panel is completely normal and bilirubin is unconjugated
• Hepatitis serologies: not needed for isolated unconjugated hyperbilirubinemia with normal enzymes (hepatitis causes conjugated hyperbilirubinemia and elevated transaminases)

Management

No treatment is required

• Gilbert syndrome is entirely benign and requires no therapy
• The mainstay of management is reassurance and education
• Inform the patient that:
  • This is a common, harmless genetic variant
  • Mild jaundice may recur intermittently, especially with fasting, illness, or stress
  • It does not progress to liver disease
  • It does not shorten lifespan (and may actually confer some cardiovascular benefit through bilirubin's antioxidant properties)
  • Future lab testing may show elevated bilirubin — inform other healthcare providers to prevent unnecessary repeat workup

Drug metabolism considerations

UGT1A1 metabolizes not only bilirubin but also certain drugs. Patients with Gilbert syndrome may be at increased risk of toxicity from medications that rely on UGT1A1 for glucuronidation:

Drug	Clinical relevance	Risk
Irinotecan (chemotherapy)	Active metabolite SN-38 accumulates → severe diarrhea and myelosuppression	Life-threatening; FDA recommends UGT1A1 genotyping before prescribing
Atazanavir, indinavir (HIV protease inhibitors)	Inhibit UGT1A1 → worsened hyperbilirubinemia, visible jaundice	Usually cosmetic only; rarely requires drug change
Acetaminophen	Glucuronidation is a minor pathway; some Gilbert syndrome patients may have reduced clearance	Unlikely to be clinically significant at therapeutic doses; avoid excessive doses
Morphine	Glucuronidated by UGT enzymes	Theoretical risk of prolonged effect; monitor
Lorazepam, oxazepam	Glucuronidated benzodiazepines	Theoretical risk; clinical significance uncertain
Lamotrigine	Glucuronidated by UGT1A4 (related enzyme)	May require dose adjustment
NSAIDs	Some are glucuronidated	Clinical significance unclear in Gilbert syndrome

• Do NOT reduce chemotherapy doses based on elevated bilirubin alone in Gilbert syndrome patients — the bilirubin elevation reflects impaired conjugation, not hepatic dysfunction; dose adjustments based on bilirubin as a surrogate for liver function are inappropriate in this context

Disposition

• Discharge home — Gilbert syndrome is not a reason for admission, further ED workup, or specialist referral
• Clear documentation: note the diagnosis in the chart to prevent future unnecessary workup
• Reassurance is the treatment: many patients are anxious about jaundice or "abnormal liver labs" — explain that this is a benign genetic variant shared by millions of people
• Outpatient follow-up: with primary care physician for routine monitoring (no specific hepatology follow-up needed unless diagnostic uncertainty remains)
• Advise the patient to:
  • Inform future healthcare providers of their Gilbert syndrome diagnosis
  • Maintain regular meals and hydration (fasting exacerbates jaundice)
  • Report any new symptoms (abdominal pain, dark urine, pale stools, pruritus, persistent fatigue) — these would suggest a different diagnosis

See Also

• Neonatal jaundice
• Neonatal hepatitis
• Crigler-Najjar syndrome
• Hemolytic anemia
• G6PD deficiency
• Hereditary spherocytosis
• Wilson disease

External Links

• StatPearls — Gilbert Syndrome
• J Hepatol — Gilbert's syndrome revisited (2023)
• MedlinePlus — Gilbert Syndrome
• NCBI Bookshelf — Irinotecan Therapy and UGT1A1 Genotype